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diagnostic yield of 2-[18F]-fluoro-2-deoxy-D-glucose-Positron-Emission-
Tomography/Computed-Tomography (FDG-PET/CT) in Fever of Unknown Origin
(FUO).
Materials and Methods: Study-ID CRD42016032696. Four databases were searched
for studies of FDG-PET/CT in FUO 1/1/2000-1/12/2015. Exclusions were non-English
language, case reports, non-standard FDG-radiotracer and significant missing data.
Quality was assessed by two authors independently using a standardised tool. Pooled
diagnostic yield was calculated using a random-effects model. An iterative electronic
and face-to-face Delphi generated interspeciality consensus.
Results: Pooled diagnostic yield was 56% (95%CI 50-61%), I2=61%, 18 studies and
905 patients. Only 5 studies reported results of previous imaging, and sub-group
analysis estimated diagnostic yield beyond conventional CT at 32% (95%CI 22-44%),
I2=66%. Consensus was established that FDG-PET/CT is increasingly available with
an emerging role, but there is prevailing variability in practice.
Conclusion: There is insufficient evidence to support the value of FDG-PET/CT in
investigative algorithms of FUO. We need a paradigm shift in research, involving
prospective studies recruiting at diagnosis of FUO, with updated case definitions and
hard outcome measures. While these studies will be a significant undertaking with
multi-centre collaboration, their completion is vital for balancing both radiation
exposure and costs against possible benefits of utilising FDG-PET/CT.
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Aim: To perform a systematic review, meta-analysis and Delphi exercise to evaluate diagnostic yield 
of 2-[18F]-fluoro-2-deoxy-D-glucose-Positron-Emission-Tomography/Computed-Tomography (FDG-
PET/CT) in Fever of Unknown Origin (FUO). 
Materials and Methods: Study-ID CRD42016032696. Four databases were searched for studies of 
FDG-PET/CT in FUO 1/1/2000-1/12/2015. Exclusions were non-English language, case reports, non-
standard FDG-radiotracer and significant missing data. Quality was assessed by two authors 
independently using a standardised tool. Pooled diagnostic yield was calculated using a random-
effects model. An iterative electronic and face-to-face Delphi generated interspeciality consensus. 
Results: Pooled diagnostic yield was 56% (95%CI 50-61%), I2=61%, 18 studies and 905 patients. Only 
5 studies reported results of previous imaging, and sub-group analysis estimated diagnostic yield 
beyond conventional CT at 32% (95%CI 22-44%), I2=66%. Consensus was established that FDG-
PET/CT is increasingly available with an emerging role, but there is prevailing variability in practice. 
Conclusion: There is insufficient evidence to support the value of FDG-PET/CT in investigative 
algorithms of FUO. We need a paradigm shift in research, involving prospective studies recruiting at 
diagnosis of FUO, with updated case definitions and hard outcome measures. While these studies 
will be a significant undertaking with multi-centre collaboration, their completion is vital for 
balancing both radiation exposure and costs against possible benefits of utilising FDG-PET/CT. 
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CI  Confidence Intervals 7 
FDG-PET/CT 2-[18F]-fluoro-2-deoxy-D-glucose - Positron Emission Tomography/Computed 8 
Tomography  9 
FUO  Fever of Unknown Origin 10 
IQR  Interquartile Range 11 
IUO  Inflammation of Unknown Origin 12 
KPI  Key Performance Indicator  13 
Manuscript
2 
 
Introduction 14 
Fever as an isolated clinical presentation has challenged clinicians for decades1, 2. In 1961 Petersdorf 15 
and Beeson provided a case definition for ‘fever (or pyrexia) of unknown origin’: 1) a body 16 
temperature above 38.3°C; 2) on several occasions; with 3) a duration of illness of at least three 17 
weeks; and 4) no diagnosis within one week of hospital admission2-4. Fifty years on, definitions of 18 
FUO and the spectrum of aetiologies have evolved, however the diagnostic challenges remain4. FUO 19 
represents an estimated 2.9% of hospital admissions, with morbidity associated with prolonged 20 
hospital stay, repeated cycles of invasive investigations and presumptive treatment, mortality rates 21 
between 12-35%, and cost implications5.   22 
2-[18F]-fluoro-2-deoxy-D-glucose (FDG)-Positron-Emission-Tomography/Computed-Tomography 23 
(PET/CT) emerged at the end of the 20th century as an amalgamation between functional and 24 
conventional anatomical imaging6. Its role in oncological staging has been well-defined, however in 25 
other specialities there is less clarity7. Specifically, in the investigation of FUO the role of FDG-PET/CT 26 
in clinical practice and diagnostic algorithms is inconsistent and unestablished. Existing guidelines 27 
suggest that FDG-PET/CT may be used where conventional investigations have not revealed a 28 
source8.  29 
FDG-PET/CT is not associated with nephrotoxicity, and standard protocols expose patients to less 30 
radiation than a conventional CT. An average FDG-PET/CT scan exposes a patient to 15mSv radiation, 31 
approximately 5-6 years background radiation, rather than 20-25mSv in a contrast-enhanced chest-32 
abdomen-pelvis CT. Other advantages include imaging areas (e.g. head and neck, extremities) which 33 
are beyond the range of most CT scans used in this context, and detection of vascular and truncal 34 
musculoskeletal inflammation for which cross-sectional contrast CT imaging is insensitive. The main 35 
caveats are cost and accessibility, FDG-PET/CT costing ₤800, compared to ₤250 for a contrast-36 
enhanced chest-abdomen-pelvis CT. However this could easily be remunerated by earlier definitive 37 
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treatment associated with additional diagnostic sensitivity. A marginally reduced length of inpatient 38 
stay could mitigate the cost, with an average ₤400 for one night hospital admission9.  39 
Current literature evaluating the role of FDG-PET/CT in FUO is based on observational data involving 40 
small samples, outdated case definitions, and poor generalisability. Outcomes reported by existing 41 
meta-analyses focus on sensitivity of FDG-PET/CT in FUO10, 11. Sensitivity refers to the proportion of 42 
cases with a diagnosis to explain the FUO for which FDG-PET/CT contributed to the diagnosis, or 43 
A/(A+B) (Table 1). This is statistically inappropriate as there is no reference standard for the 44 
investigation of FUO to enable estimates of diagnostic accuracy12. In comparison, ‘diagnostic yield’ 45 
provides a more suitable outcome measure, calculated as the proportion of all FDG-PET/CT scans 46 
(both normal and abnormal) that contribute to the diagnosis of FUO, A/(A+B+C+D) ( Table 1)13. 47 
Strikingly, there has been limited analysis of diagnostic yield of FDG-PET/CT beyond that of 48 
conventional CT. Further, previous meta-analyses have not studied individual patient data. 49 
 50 
Table 1   51 
 52 
We performed an up-to-date meta-analysis of the diagnostic yield of FDG-PET/CT in all patients with 53 
FUO. Secondary outcomes included the proportion with an abnormal FDG-PET/CT, final diagnosis, 54 
false positive results and mortality. The results of the meta-analysis were used to inform two rounds 55 
of a Delphi survey and a half-day meeting, to develop a consensus on the current knowledge on the 56 
role of FDG-PET/CT in FUO and inform future research.       57 
  58 
4 
 
Materials and Methods 59 
 60 
Systematic Review and Meta-analysis 61 
The protocol was prospectively registered with PROSPERO, an online international database of 62 
systematic reviews (Study-ID CRD42016032696). It adhered to PRISMA guidelines. QUADAS-2, 63 
STROBE, Cochrane guidelines and MOOSE guidelines were also utilised14-17.  64 
Inclusion and Exclusion criteria: All patients were included irrespective of age, comorbidities or 65 
immunocompromise. Inclusion criteria for FDG-PET/CT protocols were not defined, provided they 66 
involved a standard [18]-FDG radiotracer. Exclusion criteria were case reports, significant missing 67 
data such that the primary outcome could not be calculated and non-English studies.  68 
Search strategy and study detection: See Table 2.  69 
 70 
Table 2 71 
 72 
Methodological quality assessment: Two authors (TB&AR) independently performed the quality 73 
assessment and used this to identify studies to be included in the meta-synthesis. Disagreements 74 
were resolved by a third author (SS). Existing research is restricted to case series and, in the absence 75 
of comparison with a reference standard, these cannot be interpreted as diagnostic accuracy 76 
studies. For this reason a specific quality assessment tool was utilised, with nine criteria scored as 77 
‘High’, ‘Unclear’ or ‘Low’ risk of bias, see Supplement18. Each study is given a quality rating ‘Poor’, 78 
‘Fair’ and ‘Good’, and quality assessment are summarised in Figure 3. The studies included in the 79 
inter-rater agreement on the quality assessment is evaluated by a calculated kappa statistic, with 80 
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95% confidence intervals (CIs) ranging from zero (completely chance-explained agreement) and one 81 
(perfect agreement)19.  82 
Data extraction: A data extraction form was developed using Microsoft Excel, see Supplement, and 83 
two authors (TB&R) independently piloted the form and subsequently performed the data 84 
extraction. Disagreements were resolved by a third author (SS). Authors of included studies were 85 
contacted for missing data.   86 
Analysis: A qualitative synthesis and summary was performed. Results for studies included in the 87 
quantitative analysis were calculated as proportions, with meta-analysis performed using a random-88 
effects model in Stata.13 to produce a summary outcome proportion with 95% CIs, and I2 statistic for 89 
heterogeneity. Sensitivity analyses was performed to exclude poor quality studies. Sub-group 90 
analyses were performed for immunocompetent adults.    91 
  92 
Delphi Consensus 93 
The Delphi technique is an accepted method for generating consensus in a wide variety of 94 
disciplines20-22. It involves multiple iteration questionnaire surveys with anonymous and unbiased 95 
methods. This study included 2-rounds of sequential pre-tested questionnaires, and a half-day face-96 
face meeting. The working-group included 30 UK-based clinicians with expertise in Epidemiology, 97 
Research Methods, and Clinical Practice in the specialities of Nuclear Medicine, Radiology, Infectious 98 
Diseases, Rheumatology, Haematology and General Medicine. The questionnaires were developed, 99 
refined and administered, each consisting of single and multiple answer questions, free-text 100 
comments, and 5-point Likert agreement scales. An initial survey was performed in 2015 before the 101 
face-to-face meeting and consisted of 12 questions. After the meeting, a refined survey with 22 102 
questions was performed. The surveys and discussion surrounded the current evidence and available 103 
guidelines, availability of FDG-PET/CT, working case-definitions of FUO, position of FDG-PET/CT in 104 
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diagnostic algorithms of FUO, and potential factors involved in improving the outcomes in the 105 
application of FDG-PET/CT. There was also a focus on the future direction of research. Consensus in 106 
surveys (Supplement) was accepted if agreement (participants responding ‘Strongly agree’ or 107 
‘Agree’) was over 60%.  108 
  109 
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Results 110 
 111 
Systematic review and Meta-analysis 112 
Study Selection: 22 studies were identified for the qualitative synthesis, and the quality assessment 113 
selected 18 studies with a total of 905 patients for meta-analysis, see Figure 1. Interrater agreement 114 
between reviewers was 91% with Kappa 0.85 and P<0.001. Reasons for exclusions are displayed in 115 
Supplementary Data23-26.  116 
 117 
Figure 1 118 
 119 
Quality Assessment and Study Design: The qualitative assessment demonstrated a high risk of bias 120 
across all the included studies, see Figure 2. All the studies were observational case series with no 121 
comparison group. They were largely (89%) retrospective, involving recruitment from the Nuclear 122 
Medicine Department databases of patients referred for the indication of a FUO. The studies were 123 
largely confined to tertiary care centres, and were geographically widely distributed across 15 124 
different countries in Europe and Asia. The median sample size was 48 (Interquartile range, IQR 24-125 
74), with a median sample size per year 22 (IQR 8-29). The year of commencement of the studies 126 
ranged from 2003-2010 (median 2007, IQR 2005-2007), with the year of publication ranging from 127 
2008-2015 (median 2012, IQR 2010-2013). The median study duration was 35 (IQR 23-49) months. 128 
There is insufficient data to report the proportion of children. Three studies included children and 129 
none were exclusively performed in children. 50% of the over-all population was female. 10 (56%) 130 
studies excluded immunocompromised patients.     131 
 132 
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Figure 2 133 
 134 
Case definitions: The included studies largely reported standardised case definitions of FUO as a 135 
fever for 3 weeks with at least one documented fever over 38’c (17, 94%). There was minimal 136 
documentation on the duration of symptoms prior to admission or the length of inpatient stay. 137 
Patients were referred to the nuclear medicine department for FDG-PET/CT at the discretion of the 138 
responsible clinician. One study mandated discussion at a multidisciplinary meeting prior to referral.  139 
Intervention: 17 (94%) studies reported details of their FDG-PET/CT protocols. The protocols 140 
demonstrate the studies utilised the same radiotracer injected at a standard interval of 60-90 mins 141 
prior to scan. 7 (39%) used IV and/or oral contrast. It was notable that at least 4 (28%) studies 142 
utilised high-dose CT. One study incorporated a 24 hour carbohydrate restricted diet prior to the 143 
scan to reduce non-specific cardiac uptake. No studies reported independent assessors interpreting 144 
the scans, however 7 (39%) reported the involvement of discussion between two assessors, usually a 145 
nuclear medicine physician and a radiologist. 146 
Primary outcome: A meta-analysis of 18 studies suggest an overall diagnostic contribution of 56% 147 
(95% CI 50-61%), I2 61% of FDG-PET/CT in all patients with FUO, illustrated in the forest plot in Figure 148 
3. Sub-group analysis for diagnostic contribution in 1) adults, 2) immunocompetent patients 149 
(‘classical FUO’), 3) immunocompetent adults and 4) immunocompetent adults without contrast 150 
reduced the heterogeneity in the model, however the point estimate of diagnostic yield remained 151 
largely unchanged, Forest Plots included in Supplementary Data.  152 
Previous cross-sectional imaging and added contribution of FDG-PET/CT: There were sparse data on 153 
the documentation or results of previous imaging. Previous investigations were reported in 12 (67%) 154 
studies, with a median 51% (IQR 27-81%) receiving a CT prior to referral for FDG-PET/CT. Out of 155 
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these, 5 studies reported the results of previous imaging. A sub-group analysis of these data suggest 156 
the diagnostic yield of FDG-PET/CT over CT is 32% (95% CI 22-44%), I2 66%.  157 
 158 
Figure 3 159 
 160 
Secondary outcomes 161 
Meta-analysis of the proportion with an abnormal FDG-PET/CT produced an overall result of 69% 162 
(95% CI 63-75%), I2 72. The higher proportion of abnormal scans was accounted for by a proportion 163 
of ‘false positives’, abnormal scans with no contribution to the final diagnosis, with an overall result 164 
of 9% (95% CI 5-14%), I2 72. The overall estimate was low which is reassuring but there was striking 165 
variation across individual studies, between 0 to 33% reported false positive scans.  166 
73% (95% CI 68-78%) had a final diagnosis, mainly corresponding with three categories: infectious 167 
diseases representing 30% (95% CI 26-35%), inflammatory causes 20% (95% CI 17-24%) and 168 
malignancy 13% (95% CI 9-17%), data included in Supplementary Text. Individual patient data 169 
extraction from 16/18 studies, totalling 749 patients facilitated stratification of diagnoses that did 170 
and did not benefit from FDG-PET/CT, illustrated in Figures 4-6.  171 
The presence of raised inflammatory markers were reported in 7 (39%) studies, and there were 172 
insufficient data to suggest any association with contribution of FDG-PET/CT to diagnosis.  173 
Methods for the establishment of the final diagnosis were not uniformly reported, however existing 174 
data suggests a variety of methods including bone marrow, lymph node, tissue biopsy, serology, 175 
microbiology cultures, immunology and autopsy.  176 
There were limited data on the period of follow-up and final outcomes of patients. 12 (67%) studies 177 
reported the length of follow-up, with median 6 (IQR 6-12) months. 178 
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 179 
Figures 4-6 180 
 181 
Delphi Consensus 182 
31/40 (78%) participants responded to the initial Delphi survey. 22/40 (55%) attended the face-to-183 
face meeting. 30/40 (75%) responded to the second Delphi. The initial Delphi survey consisted of 184 
three parts aiming to assess 1) availability of FDG-PET/CT for FUO, 2) clinical practice in requesting of 185 
FDG-PET/CT for FUO, and 3) decision-making in a hypothetical case of FUO, see Supplementary Data 186 
for the full questionnaire. While 100% reported access to FDG-PET/CT, there was wide-variability in 187 
reported time from referral to FDG-PET/CT ranging from 2 days to 2 weeks (UK Key Performance 188 
Indicator, KPI 5 days), and time to reporting of scans ranging from 1 day to 1 week (UK KPI 2days). 189 
There was widespread agreement (87% responders) that FDG-PET/CT does have a role in the 190 
investigation of unknown origin (suggested to be 56%), however there was little consensus on sub-191 
groups or factors that might improve the diagnostic yield. There was also agreement in the value of 192 
re-assessing patients for developing symptoms and signs, involving other specialities during the 193 
investigation process, and involvement of nuclear medicine physicians in case discussions. The initial 194 
survey demonstrated consensus of opinions that false positives needed to be taken into account in 195 
the decision to refer, that FDG-PET/CT has a high negative predictive value and that false negatives 196 
may arise due to empirical steroids.  197 
The face-to-face meeting involved a presentation of the results of the systematic review, meta-198 
analysis and initial Delphi survey, with sufficient time for questions and discussion. There were 199 
focussed debate surrounding the case-definition of FUO, investigations required and priority 200 
outcomes. The meeting identified the variability in access and knowledge of FDG-PET/CT, the 201 
heterogeneity and updated working definitions of FUO and dearth of evidence but encouraging 202 
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results in clinical practice. It highlighted the need for clinicians to be aware of the deficits of FDG-203 
PET/CT: not always imaging the brain, low sensitivity for cardiac and renal tract pathology and 204 
reduced gastrointestinal uptake with certain medication. In contrast to previous opinions, there is no 205 
evidence for poor glycaemic control as a contraindication to FDG-PET/CT. Further, the fact that low-206 
contrast imaging is incorporated into standard protocols does reduce the resolution as compared to 207 
conventional contrast-CT. It was agreed that certain circumstances affect decision-making, e.g. renal 208 
impairment, suitability for invasive tests and recent surgery. The meeting concluded with dialogue 209 
on prospects and feasibility of future research. Current practice incorporates FDG-PET/CT late in 210 
diagnostic algorithms, however there was acknowledgement that it may have a role as a ‘front-211 
loaded’ investigation in a subset of patients. This has potential to speed diagnosis, reduced radiation 212 
exposure and shorten hospital stay, maybe reduce mortality.  213 
The second Delphi aimed to develop agreement on a case definition of FDG-PET/CT, basic 214 
investigations required and resolve disagreement to questions. The participants agreed that a febrile 215 
illness for 2 weeks and without immediate diagnostic clues worked for their practice was a clinically 216 
acceptable definition. They agreed the definition should incorporate ‘Inflammation of Unknown 217 
Origin’, IUO, unexplained symptoms for 2 weeks with raised inflammatory markers. Specific 218 
investigations prior to PET imaging were deemed important, including a cross-sectional CT, TTE and 219 
specific serology (see supplementary data). However there was also agreement that a front-loaded 220 
FDG-PET/CT prior to conventional imaging may have a role. There was indecision about whether 221 
antibiotics should be delayed prior to FDG-PET/CT. Priorities in the outcome of a formal analysis of 222 
the benefit of front-loaded PET/CT, in the order of importance (most to least important) were 1) 223 
Time to diagnosis, 2) Time to treatment, 3) Mortality, 4) Side-effects of investigations/ treatment 224 
and 5) Time to discharge.       225 
  226 
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Conclusion 227 
PET is a functional imaging tool that provides added information about site and intensity of active 228 
metabolism, and so unsurprisingly has found its way into the diagnostic pathway of the febrile 229 
patient. However it is expensive, lacks specificity and needs adequate evidence for its diagnostic 230 
role. This meta-analysis suggests that a diagnostic yield was achieved in 56% (95% CI 50-61%) 231 
performed. The results are consistent with previous results of 54% ‘overall helpfulness’ (synonymous 232 
with diagnostic yield) in a meta-analysis of 10 studies27. Two meta-analyses reviewing sensitivity 233 
reported 85% (95% CI 81-88%; 15 studies) and 98% (95% CI 94-99%; 9 studies).  234 
The results are based on results of case series, involving convenience sampling of FUO patients 235 
referred to Nuclear Medicine departments at the discretion of the responsible physician. Specifically, 236 
recruitment is not at the point of diagnosis of fever of unknown origin, and there is no control group. 237 
Patient recruitment may favour patients with renal impairment, poor fitness for invasive biopsies, 238 
and exclude patients taking metformin, recent surgery or unable to lie still. The room for bias is high 239 
and these important patient characteristics are poorly documented in the included studies.    240 
It is also striking that reported diagnostic yield does not address contribution beyond conventional 241 
imaging as all the patients did not undergo conventional imaging, and reporting of those that did 242 
was inconsistent. 5 studies included in this meta-analysis reported results of previous imaging. A 243 
sub-group analysis of these data suggest the diagnostic yield of FDG-PET/CT beyond CT is 32% 244 
(95%CI 22-44%) with significant heterogeneity (I2 66%).  245 
Case definitions of FUO adhered to outdated definitions that were established based on minimal 246 
evidence. It is accepted that subsets of patients do not mount any fever, and for this reason it has 247 
been suggested that IUO be included in future research. The definition also encompasses an 248 
extensive list of diagnoses and possibilities, is geographically diverse and limited by resources.  249 
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FDG-PET/CT is perceived to be an objective intervention. However there is minimal data on inter-250 
reporter agreement, and none of the studies involved independent reporting by more than one 251 
radiologist. Importantly the protocols frequently included nephrotoxic contrast, and high dose 252 
attenuation CTs. Not only may this bias the outcome, but it demonstrates potential risks associated 253 
with the scans. There is evidence that a special diet to reduce cardiac non-specific cardiac uptake 254 
may improve outcomes, however the only study that included this protocol did not report cardiac 255 
diagnoses.   256 
There is no diagnostic reference standard for FUO, and many patients remain undiagnosed. 257 
Furthermore there is a level of ambiguity in final diagnoses made by clinicians, and the impression of 258 
whether the FDG-PET/CT contributed to the diagnosis. In most studies this was based on the result 259 
of the FDG-PET/CT being compatible with the final diagnosis, however it did not demonstrate a 260 
diagnostic yield over conventional imaging. Outcome measures need to be relevant to hard patient 261 
outcomes and to current health systems processes. While sensitivity is not an appropriate outcome 262 
measure, diagnostic yield may also overestimate the contribution and does not indicate the clinical 263 
impact of the scan. Other possible outcomes include evaluating time to treatment, discharge or 264 
mortality.  265 
It is evident that studies included patients that had not had conventional cross-sectional imaging. 266 
Furthermore, a referral for FDG-PET/CT was frequently made in spite of pathology identified on 267 
cross-sectional imaging that could undergo alternative, more specific and objective investigation 268 
such as a biopsy. With this is mind, the question of diagnostic yield of FDG-PET/CT beyond 269 
abnormalities detected by cross-sectional imaging is clinically important.  270 
The individual patient meta-analysis is limited by the low quality of included studies. It does provide 271 
suggestion of diagnoses that did and did not benefit from FDG-PET/CT, see Figures 4-6. It is rational 272 
that viral infections, urinary tract infections, bacteraemias and small vessel vasculitides are not easily 273 
detected on FDG-PET/CT. There are limitations in interpretation of FDG avidity in the brain, heart 274 
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and urinary tract. The brain and the heart have high glucose uptake and the urinary tract 275 
concentrates FDG during excreted.   276 
This study provides a rigorous, updated and balanced insight into current evidence for the role of 277 
FDG-PET/CT in FUO. It demonstrates a lack of evidence supporting the value and positioning of FDG-278 
PET/CT in investigative algorithms. The Delphi survey enabled the working group to interpret results 279 
in line with current practice, and explore directions for research. It highlighted the need for a 280 
paradigm shift in research, involving prospective studies recruiting at the point of diagnosis of FUO, 281 
with updated case definitions and hard outcome measures.  While these studies will be a significant 282 
undertaking with multi-centre collaboration, their completion is vital for balancing both radiation 283 
exposure and costs against the possible benefits of utilising FDG-PET/CT.  284 
 285 
  286 
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Figure and Table Legends 287 
 288 
Figure 1: Flow diagram of study selection. 289 
 290 
Figure 2: Summary of the Quality Assessment of Included Studies Using the NIH Tool 291 
 292 
Figure 3: Diagnostic Yield of FDG-PET/CT in Fever of Unknown Origin (n=18), Proportion 0=0% to 293 
1=100% +/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 294 
moderate heterogeneity.  295 
 296 
Figure 4: Infections (n=241; 32% of final diagnosis): Diagnostic yield from PET/CT 297 
 298 
Figure 5: Inflammatory/ Autoimmune (n=171; 20% of final diagnosis): Diagnostic yield from PET/CT 299 
 300 
Figure 6: Malignancy (n=112; 13% of final diagnoses): Diagnostic yield from PET/CT 301 
 302 
Table 1: 2x2 table categorising possible study outcomes.   303 
 304 
Table 2: Search Strategy and Study Selection 305 
 306 
 307 
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Introduction 14 
Fever as an isolated clinical presentation has challenged clinicians for decades1, 2. In 1961 Petersdorf 15 
and Beeson provided a case definition for ‘fever (or pyrexia) of unknown origin’: 1) a body 16 
temperature above 38.3°C; 2) on several occasions; with 3) a duration of illness of at least three 17 
weeks; and 4) no diagnosis within one week of hospital admission2-4. Fifty years on, definitions of 18 
FUO and the spectrum of aetiologies have evolved, however the diagnostic challenges remain4. FUO 19 
represents an estimated 2.9% of hospital admissions, with morbidity associated with prolonged 20 
hospital stay, repeated cycles of invasive investigations and presumptive treatment, mortality rates 21 
between 12-35%, and cost implications5.   22 
2-[18F]-fluoro-2-deoxy-D-glucose (FDG)-Positron-Emission-Tomography/Computed-Tomography 23 
(PET/CT) emerged at the end of the 20th century as an amalgamation between functional and 24 
conventional anatomical imaging6. Its role in oncological staging has been well-defined, however in 25 
other specialities there is less clarity7. Specifically, in the investigation of FUO the role of FDG-PET/CT 26 
in clinical practice and diagnostic algorithms is inconsistent and unestablished. Existing guidelines 27 
suggest that FDG-PET/CT may be used where conventional investigations have not revealed a 28 
source8.  29 
FDG-PET/CT is not associated with nephrotoxicity, and standard protocols expose patients to less 30 
radiation than a conventional CT. An average FDG-PET/CT scan exposes a patient to 15mSv radiation, 31 
approximately 5-6 years background radiation, rather than 20-25mSv in a contrast-enhanced chest-32 
abdomen-pelvis CT. Other advantages include imaging areas (e.g. head and neck, extremities) which 33 
are beyond the range of most CT scans used in this context, and detection of vascular and truncal 34 
musculoskeletal inflammation for which cross-sectional contrast CT imaging is insensitive 9. The main 35 
caveats are cost and accessibility, FDG-PET/CT costing ₤800, compared to ₤250 for a contrast-36 
enhanced chest-abdomen-pelvis CT. However this could easily be remunerated by earlier definitive 37 
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treatment associated with additional diagnostic sensitivity. A marginally reduced length of inpatient 38 
stay could mitigate the cost, with an average ₤400 for one night hospital admission10.  39 
Current literature evaluating the role of FDG-PET/CT in FUO is based on observational data involving 40 
small samples, outdated case definitions, and poor generalisability. Outcomes reported by existing 41 
meta-analyses focus on sensitivity of FDG-PET/CT in FUO11, 12. Sensitivity refers to the proportion of 42 
cases with a diagnosis to explain the FUO for which FDG-PET/CT contributed to the diagnosis, or 43 
A/(A+B) (Table 1). This is statistically inappropriate as there is no reference standard for the 44 
investigation of FUO to enable estimates of diagnostic accuracy13. In comparison, ‘diagnostic yield’ 45 
provides a more suitable outcome measure, calculated as the proportion of all FDG-PET/CT scans 46 
(both normal and abnormal) that contribute to the diagnosis of FUO, A/(A+B+C+D) ( Table 1)14. 47 
Strikingly, there has been limited analysis of diagnostic yield of FDG-PET/CT beyond that of 48 
conventional CT. Further, previous meta-analyses have not studied individual patient data. 49 
 50 
Table 1   51 
 52 
We performed an up-to-date meta-analysis of the diagnostic yield of FDG-PET/CT in all patients with 53 
FUO. Secondary outcomes included the proportion with an abnormal FDG-PET/CT, final diagnosis, 54 
false positive results and mortality. The results of the meta-analysis were used to inform two rounds 55 
of a Delphi survey and a half-day meeting, to develop a consensus on the current knowledge on the 56 
role of FDG-PET/CT in FUO and inform future research.       57 
  58 
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Materials and Methods 59 
 60 
Systematic Review and Meta-analysis 61 
The protocol was prospectively registered with PROSPERO, an online international database of 62 
systematic reviews (Study-ID CRD42016032696). It adhered to PRISMA guidelines. QUADAS-2, 63 
STROBE, Cochrane guidelines and MOOSE guidelines were also utilised15-18.  64 
Inclusion and Exclusion criteria: All patients were included irrespective of age, comorbidities or 65 
immunocompromise. Inclusion criteria for FDG-PET/CT protocols were not defined, provided they 66 
involved a standard [18]-FDG radiotracer. Exclusion criteria were case reports, significant missing 67 
data such that the primary outcome could not be calculated and non-English studies.  68 
Search strategy and study detection: See Table 2.  69 
 70 
Table 2 71 
 72 
Methodological quality assessment: Two authors (TB&AR) independently performed the quality 73 
assessment and used this to identify studies to be included in the meta-synthesis. Disagreements 74 
were resolved by a third author (SS). Existing research is restricted to case series and, in the absence 75 
of comparison with a reference standard, these cannot be interpreted as diagnostic accuracy 76 
studies. For this reason a specific quality assessment tool was utilised, with nine criteria scored as 77 
‘High’, ‘Unclear’ or ‘Low’ risk of bias, see Supplement19. Each study is given a quality rating ‘Poor’, 78 
‘Fair’ and ‘Good’, and quality assessment are summarised in Figure 3. The studies included in the 79 
inter-rater agreement on the quality assessment is evaluated by a calculated kappa statistic, with 80 
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95% confidence intervals (CIs) ranging from zero (completely chance-explained agreement) and one 81 
(perfect agreement)20.  82 
Data extraction: A data extraction form was developed using Microsoft Excel, see Supplement, and 83 
two authors (TB&AR) independently piloted the form and subsequently performed the data 84 
extraction. Disagreements were resolved by a third author (SS). Authors of included studies were 85 
contacted for missing data.   86 
Analysis: A qualitative synthesis and summary was performed. Results for studies included in the 87 
quantitative analysis were calculated as proportions, with meta-analysis performed using a random-88 
effects model in Stata.13 to produce a summary outcome proportion with 95% CIs, and I2 statistic for 89 
heterogeneity. Sensitivity analyses was performed to exclude poor quality studies. Sub-group 90 
analyses were performed for immunocompetent adults.    91 
  92 
Delphi Consensus 93 
The Delphi technique is an accepted method for generating consensus in a wide variety of 94 
disciplines21-23. It involves multiple iteration questionnaire surveys with anonymous and unbiased 95 
methods. This study included 2-rounds of sequential pre-tested questionnaires, and a half-day face-96 
face meeting. The working-group included 30 UK-based clinicians with expertise in Epidemiology, 97 
Research Methods, and Clinical Practice in the specialities of Nuclear Medicine, Radiology, Infectious 98 
Diseases, Rheumatology, Haematology and General Medicine. The questionnaires were developed, 99 
refined and administered, each consisting of single and multiple answer questions, free-text 100 
comments, and 5-point Likert agreement scales. An initial survey was performed in 2015 before the 101 
face-to-face meeting and consisted of 12 questions. After the meeting, a refined survey with 22 102 
questions was performed. The surveys and discussion surrounded the current evidence and available 103 
guidelines, availability of FDG-PET/CT, working case-definitions of FUO, position of FDG-PET/CT in 104 
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diagnostic algorithms of FUO, and potential factors involved in improving the outcomes in the 105 
application of FDG-PET/CT. There was also a focus on the future direction of research. Consensus in 106 
surveys (Supplement) was accepted if agreement (participants responding ‘Strongly agree’ or 107 
‘Agree’) was over 60%.  108 
  109 
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Results 110 
 111 
Systematic review and Meta-analysis 112 
Study Selection: 22 studies were identified for the qualitative synthesis, and the quality assessment 113 
selected 18 studies with a total of 905 patients for meta-analysis, see Figure 1. Interrater agreement 114 
between reviewers was 91% with Kappa 0.85 (95% CI 0.75-0.96). Reasons for exclusions are 115 
displayed in Supplementary Data24-27.  116 
 117 
Figure 1 118 
 119 
Quality Assessment and Study Design: The qualitative assessment demonstrated a high risk of bias 120 
across all the included studies, see Figure 2. All the studies were observational case series with no 121 
comparison group. They were largely (89%) retrospective, involving recruitment from the Nuclear 122 
Medicine Department databases of patients referred for the indication of a FUO. The studies were 123 
largely confined to tertiary care centres, and were geographically widely distributed across 15 124 
different countries in Europe and Asia. The median sample size was 48 (Interquartile range, IQR 24-125 
74), with a median sample size per year 22 (IQR 8-29). The year of commencement of the studies 126 
ranged from 2003-2010 (median 2007, IQR 2005-2007), with the year of publication ranging from 127 
2008-2015 (median 2012, IQR 2010-2013). The median study duration was 35 (IQR 23-49) months. 128 
There is insufficient data to report the proportion of children. Three studies included children and 129 
none were exclusively performed in children. 50% of the over-all population was female. 10 (56%) 130 
studies excluded immunocompromised patients.     131 
 132 
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Figure 2 133 
 134 
Case definitions: The included studies largely reported standardised case definitions of FUO as a 135 
fever for 3 weeks with at least one documented fever over 38’c (17, 94%). There was minimal 136 
documentation on the duration of symptoms prior to admission or the length of inpatient stay. 137 
Patients were referred to the nuclear medicine department for FDG-PET/CT at the discretion of the 138 
responsible clinician. One study mandated discussion at a multidisciplinary meeting prior to referral.  139 
Intervention: 17 (94%) studies reported details of their FDG-PET/CT protocols. The protocols 140 
demonstrate the studies utilised the same radiotracer injected at a standard interval of 60-90 mins 141 
prior to scan. 7 (39%) used IV and/or oral contrast. It was notable that at least 4 (28%) studies 142 
utilised high-dose CT. One study incorporated a 24 hour carbohydrate restricted diet prior to the 143 
scan to reduce non-specific cardiac uptake. No studies reported independent assessors interpreting 144 
the scans, however 7 (39%) reported the involvement of discussion between two assessors, usually a 145 
nuclear medicine physician and a radiologist. 146 
Primary outcome: A meta-analysis of 18 studies suggest an overall diagnostic contribution of 56% 147 
(95% CI 50-61%), I2 61% of FDG-PET/CT in all patients with FUO, illustrated in the forest plot in Figure 148 
3. Sub-group analysis for diagnostic contribution was performed in 1) adults, 2) immunocompetent 149 
patients (‘classical FUO’), 3) immunocompetent adults and 4) immunocompetent adults undergoing 150 
PET/CT without contrast enhancement. These analyses reduced the heterogeneity in the model, 151 
however the point estimate of diagnostic yield remained largely unchanged, Forest Plots included in 152 
Supplementary Data.  153 
Previous cross-sectional imaging and added contribution of FDG-PET/CT: There were sparse data on 154 
the documentation or results of previous imaging. Previous investigations were reported in 12 (67%) 155 
studies, with a median 51% (IQR 27-81%) receiving a CT prior to referral for FDG-PET/CT. Out of 156 
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these, 5 studies reported the results of previous imaging. A sub-group analysis of these data suggest 157 
the diagnostic yield of FDG-PET/CT over CT is 32% (95% CI 22-44%), I2 66%.  158 
 159 
Figure 3 160 
 161 
Secondary outcomes 162 
Meta-analysis of the proportion with an abnormal FDG-PET/CT produced an overall result of 69% 163 
(95% CI 63-75%), I2 72. The higher proportion of abnormal scans was accounted for by a proportion 164 
of ‘false positives’, abnormal scans with no contribution to the final diagnosis, with an overall result 165 
of 9% (95% CI 5-14%), I2 72. The overall estimate was low which is reassuring but there was striking 166 
variation across individual studies, between 0 to 33% reported false positive scans.  167 
73% (95% CI 68-78%) had a final diagnosis, mainly corresponding with three categories: infectious 168 
diseases representing 32% (95% CI 27-37%), inflammatory causes 20% (95% CI 17-24%) and 169 
malignancy 12% (95% CI 8-17%), data included in Supplementary Text. Individual patient data 170 
extraction from 16/18 studies, totalling 749 patients facilitated stratification of diagnoses that did 171 
and did not benefit from FDG-PET/CT, illustrated in Figures 4-6.  172 
The presence of raised inflammatory markers were reported in 7 (39%) studies, and there were 173 
insufficient data to suggest any association with contribution of FDG-PET/CT to diagnosis.  174 
Methods for the establishment of the final diagnosis were not uniformly reported, however existing 175 
data suggests a variety of methods including bone marrow, lymph node, tissue biopsy, serology, 176 
microbiology cultures, immunology and autopsy.  177 
There were limited data on the period of follow-up and final outcomes of patients. 12 (67%) studies 178 
reported the length of follow-up, with median 6 (IQR 6-12) months. 179 
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 180 
Figures 4-6 181 
 182 
Delphi Consensus 183 
31/40 (78%) participants responded to the initial Delphi survey. 22/40 (55%) attended the face-to-184 
face meeting. 30/40 (75%) responded to the second Delphi. The initial Delphi survey consisted of 185 
three parts aiming to assess 1) availability of FDG-PET/CT for FUO, 2) clinical practice in requesting of 186 
FDG-PET/CT for FUO, and 3) decision-making in a hypothetical case of FUO, see Supplementary Data 187 
for the full questionnaire. While 100% reported access to FDG-PET/CT, there was wide-variability in 188 
reported time from referral to FDG-PET/CT ranging from 2 days to 2 weeks (UK Key Performance 189 
Indicator, KPI 5 days), and time to reporting of scans ranging from 1 day to 1 week (UK KPI 2days). 190 
There was widespread agreement (87% responders) that FDG-PET/CT does have a role in the 191 
investigation of unknown origin (suggested to be 56%), however there was little consensus on sub-192 
groups or factors that might improve the diagnostic yield. There was also agreement in the value of 193 
re-assessing patients for developing symptoms and signs, involving other specialities during the 194 
investigation process, and involvement of nuclear medicine physicians in case discussions. The initial 195 
survey demonstrated consensus of opinions that false positives needed to be taken into account in 196 
the decision to refer, that FDG-PET/CT has a high negative predictive value and that false negatives 197 
may arise due to empirical steroids.  198 
The face-to-face meeting involved a presentation of the results of the systematic review, meta-199 
analysis and initial Delphi survey, with sufficient time for questions and discussion. There were 200 
focussed debate surrounding the case-definition of FUO, investigations required and priority 201 
outcomes. The meeting identified the variability in access and knowledge of FDG-PET/CT, the 202 
heterogeneity and updated working definitions of FUO and dearth of evidence but encouraging 203 
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results in clinical practice. It highlighted the need for clinicians to be aware of the deficits of FDG-204 
PET/CT: not always imaging the brain, low sensitivity for cardiac and renal tract pathology and 205 
reduced gastrointestinal uptake with certain medication. In contrast to previous opinions, there is no 206 
evidence for poor glycaemic control as a contraindication to FDG-PET/CT. Further, the fact that low-207 
contrast imaging is incorporated into standard protocols does reduce the resolution as compared to 208 
conventional contrast-CT. It was agreed that certain circumstances affect decision-making, e.g. renal 209 
impairment, suitability for invasive tests and recent surgery. The meeting concluded with dialogue 210 
on prospects and feasibility of future research. Current practice incorporates FDG-PET/CT late in 211 
diagnostic algorithms, however there was acknowledgement that it may have a role as a ‘front-212 
loaded’ investigation in a subset of patients. This has potential to speed diagnosis, reduced radiation 213 
exposure and shorten hospital stay, maybe reduce mortality.  214 
The second Delphi aimed to develop agreement on a case definition of FDG-PET/CT, basic 215 
investigations required and resolve disagreement to questions. The participants agreed that a febrile 216 
illness for 2 weeks and without immediate diagnostic clues worked for their practice was a clinically 217 
acceptable definition. They agreed the definition should incorporate ‘Inflammation of Unknown 218 
Origin’, IUO, unexplained symptoms for 2 weeks with raised inflammatory markers. Specific 219 
investigations prior to PET imaging were deemed important, including a cross-sectional CT, TTE and 220 
specific serology (see supplementary data). However there was also agreement that a front-loaded 221 
FDG-PET/CT prior to conventional imaging may have a role. There was indecision about whether 222 
antibiotics should be delayed prior to FDG-PET/CT. Priorities in the outcome of a formal analysis of 223 
the benefit of front-loaded PET/CT, in the order of importance (most to least important) were 1) 224 
Time to diagnosis, 2) Time to treatment, 3) Mortality, 4) Side-effects of investigations/ treatment 225 
and 5) Time to discharge.       226 
  227 
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Conclusion 228 
PET is a functional imaging tool that provides added information about site and intensity of active 229 
metabolism, and so unsurprisingly has found its way into the diagnostic pathway of the febrile 230 
patient. However it is expensive, lacks specificity and needs adequate evidence for its diagnostic 231 
role. This meta-analysis suggests that a diagnostic yield was achieved in 56% (95% CI 50-61%) 232 
performed. The results are consistent with previous results of 54% ‘overall helpfulness’ (synonymous 233 
with diagnostic yield) in a meta-analysis of 10 studies28. Two meta-analyses reviewing sensitivity 234 
reported 85% (95% CI 81-88%; 15 studies) and 98% (95% CI 94-99%; 9 studies).  235 
The results are based on results of case series, involving convenience sampling of FUO patients 236 
referred to Nuclear Medicine departments at the discretion of the responsible physician. Specifically, 237 
recruitment is not at the point of diagnosis of fever of unknown origin, and there is no control group. 238 
Patient recruitment may favour patients with renal impairment, poor fitness for invasive biopsies, 239 
and exclude patients taking metformin, recent surgery or unable to lie still. The room for bias is high 240 
and these important patient characteristics are poorly documented in the included studies.    241 
It is also striking that reported diagnostic yield does not address contribution beyond conventional 242 
imaging as all the patients did not undergo conventional imaging, and reporting of those that did 243 
was inconsistent. 5 studies included in this meta-analysis reported results of previous imaging. A 244 
sub-group analysis of these data suggest the diagnostic yield of FDG-PET/CT beyond CT is 32% 245 
(95%CI 22-44%) with significant heterogeneity (I2 66%).  246 
Case definitions of FUO adhered to outdated definitions that were established based on minimal 247 
evidence. It is accepted that subsets of patients do not mount any fever, and for this reason it has 248 
been suggested that IUO be included in future research. The definition also encompasses an 249 
extensive list of diagnoses and possibilities, is geographically diverse and limited by resources.  250 
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FDG-PET/CT is perceived to be an objective intervention. However there is minimal data on inter-251 
reporter agreement, and none of the studies involved independent reporting by more than one 252 
radiologist. Importantly the protocols frequently included nephrotoxic contrast, and high dose 253 
attenuation CTs. Not only may this bias the outcome, but it demonstrates potential risks associated 254 
with the scans. There is evidence that a special diet to reduce cardiac non-specific cardiac uptake 255 
may improve outcomes, however the only study that included this protocol did not report cardiac 256 
diagnoses.   257 
There is no diagnostic reference standard for FUO, and many patients remain undiagnosed. 258 
Furthermore there is a level of ambiguity in final diagnoses made by clinicians, and the impression of 259 
whether the FDG-PET/CT contributed to the diagnosis. In most studies this was based on the result 260 
of the FDG-PET/CT being compatible with the final diagnosis, however it did not demonstrate a 261 
diagnostic yield over conventional imaging. Outcome measures need to be relevant to hard patient 262 
outcomes and to current health systems processes. While sensitivity is not an appropriate outcome 263 
measure, diagnostic yield may also overestimate the contribution and does not indicate the clinical 264 
impact of the scan. Other possible outcomes include evaluating time to treatment, discharge or 265 
mortality.  266 
It is evident that studies included patients that had not had conventional cross-sectional imaging. 267 
Furthermore, a referral for FDG-PET/CT was frequently made in spite of pathology identified on 268 
cross-sectional imaging that could undergo alternative, more specific and objective investigation 269 
such as a biopsy. With this is mind, the question of diagnostic yield of FDG-PET/CT beyond 270 
abnormalities detected by cross-sectional imaging is clinically important.  271 
The individual patient meta-analysis is limited by the low quality of included studies. It does provide 272 
suggestion of diagnoses that did and did not benefit from FDG-PET/CT, see Figures 4-6. It is rational 273 
that viral infections, urinary tract infections, bacteraemias and small vessel vasculitides are not easily 274 
detected on FDG-PET/CT. There are limitations in interpretation of FDG avidity in the brain, heart 275 
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and urinary tract. The brain and the heart have high glucose uptake and the urinary tract 276 
concentrates FDG during excreted.   277 
This study provides a rigorous, updated and balanced insight into current evidence for the role of 278 
FDG-PET/CT in FUO. It demonstrates a lack of evidence supporting the value and positioning of FDG-279 
PET/CT in investigative algorithms. The Delphi survey enabled the working group to interpret results 280 
in line with current practice, and explore directions for research. It highlighted the need for a 281 
paradigm shift in research, involving prospective studies recruiting at the point of diagnosis of FUO, 282 
with updated case definitions and hard outcome measures.  While these studies will be a significant 283 
undertaking with multi-centre collaboration, their completion is vital for balancing both radiation 284 
exposure and costs against the possible benefits of utilising FDG-PET/CT.  285 
Lastly, there is no doubt that the application of FDG-PET/CT is a rapidly evolving field. This review did 286 
not cover emerging evidence from new modalities and tracers, such as FDG-leucocyte or Gallium-287 
labelled imaging 29.   288 
 289 
  290 
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Figure and Table Legends 291 
 292 
Figure 1: Flow diagram of study selection. 293 
 294 
Figure 2: Summary of the Quality Assessment of Included Studies Using the NIH Tool 295 
 296 
Figure 3: Diagnostic Yield of FDG-PET/CT in Fever of Unknown Origin (n=18), Proportion 0=0% to 297 
1=100% +/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 298 
moderate heterogeneity.  299 
 300 
Figure 4: Infections (n=241; 32% of final diagnosis): Diagnostic yield from PET/CT 301 
 302 
Figure 5: Inflammatory/ Autoimmune (n=171; 20% of final diagnosis): Diagnostic yield from PET/CT 303 
 304 
Figure 6: Malignancy (n=112; 12% of final diagnoses): Diagnostic yield from PET/CT 305 
 306 
Table 1: 2x2 table categorising possible study outcomes.   307 
 308 
Table 2: Search Strategy and Study Selection 309 
 310 
 311 
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Table 1: 2x2 table categorising possible study outcomes.   
[A] True Positives: Patients with an abnormal FDG-PET/CT 
that contributed to diagnosing the cause of the FUO.  
[B] False Negatives: Patients with a normal FDG-PET/CT 
that received a diagnosis by other means. 
[C] False Positive: Patients with an abnormal FDG-PET/CT 
that did not contribute to diagnosing the FDG-PET/CT. 
[D] True Negative: Patients with a normal FDG-PET/CT 
that remained undiagnosed after investigation or follow-
up. 
 
  
Tables
Table 2: Search Strategy and Study Selection 
Search Strategy:  
Electronic searches were performed 1/12/15 in Medline, Embase, Web of Science and Cochrane Central Register of 
Controlled Trials.  
All subheadings were included.  
Hand-searching references was performed for included studies and identification of unpublished work was attempted 
by contacting experts and reviewing conference abstracts. 
MESH terms: Ovid Medline: (‘Tomography Positron-Emission' OR ‘Fluorodeoxyglucose F18’) AND ('Fever’ exploded). 
EMBASE: ('Positron Emission Tomography' OR ‘Fluorodeoxyglucose F18’) AND ('Fever’ exploded).  
Keyword searches for ('Positron Emission* OR ‘PET*’ OR ‘fluorodeoxyglucose*’ OR ‘fludeoxyglucose*’ OR 
‘18fluorodeoxyglucose*’ OR ’fdg*’ OR ’ffdg*’ OR ’18fdg*’ OR ‘18ffdg*’ OR ’(18)ffdg*’ OR ’(18)fdg*’ OR 
‘2fluoro2deoxyglucose*’ OR ‘2 fluoro 2 deoxyglucose*’ OR ‘2 fluoro 2 deoxy d glucose*’) in combination with ('Fever’ 
OR ‘Pyrexia’ OR ‘Febrile’ OR ‘PUO’ OR ‘FUO’). 
Study selection: One author (TB) performed the de-duplication of records in EndNote XL, screened titles and excluded 
irrelevant publications. TB reviewed abstracts and/or full texts to identify eligibility for inclusion in the qualitative 
synthesis.     
 
 
 
Supplements 
 
1) Quality Assessment Tool 
http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-
reduction/tools/case_series  
 
 
  
Supplementary material (for review)
2) Data extraction form 
Study ID  
First author  
Year of Publication  
Country 
Sample size 
Start Year 
Duration (in months)  
Age range and Median age  
Percentage of Female patients included  
Study design and inclusions: 
Case definition for FUO  
Duration of symptoms prior to FDG-PET/CT  
Inpatient stay prior to FDG-PET/CT  
Study excluded immunocompromised patients  
Study design (Retrospective; Consecutive; In/outpatients)  
Patients excluded due to missing data and explanation  
Prior diagnostic investigations documented 
Outcomes: 
Primary outcome: FDG-PET/CT Diagnostic Yield  
Secondary Outcomes:  
Abnormal FDG-PET/CT  
False Positives  
Final Diagnosis  
-Infection 
-Inflammation   
-Malignancy  
Mortality 
Prior CT 
Diagnostic yield over CT 
%abnormal inflammatory markers in the group with diagnostic yield  
Basis of diagnosis  
Outcome  
Follow-up 
 
3) Delphi survey 
See attached documents 
  
4) Studies included in the qualitative synthesis 
 Author/ Year Country Sample 
size 
Study design Inclusion in Meta-
analysis 
1. Balink 2009 Netherlands 68 Retrospective case series  Yes 
2. Becerra Nakayo 2012 Spain 20 Retrospective case series; 
Only immunocompetent 
Yes 
3. Bharucha 2013 UK 33 Retrospective case series; 
Only immunocompetent 
No- Reported dIfferent 
outcome.  
4. Buch-Olsen 2014 Netherlands 57 Retrospective case series Yes 
5. Castaigne 2009 Belgium 10 Retrospective case series No- Only HIV patients 
and only reviewed 
abnormal scans. 
6. Crouzet 2012 France 79 Retrospective case series; 
Only immunocompetent 
Yes 
7. Ergul 2011 Turkey 24 Retrospective case series; 
Only immunocompetent 
Yes 
8. Federici 2010 France 10 Retrospective case series; 
Only immunocompetent 
Yes 
9. Ferda 2010 Czech Rep. 48 Retrospective case series Yes 
10. Gafter-Gvili 2015 Israel 112 Retrospective case series Yes 
11. Jasper 2010 Germany  30 Retrospective case series No- Combined results 
for FDG-PET and FDG-
PET/CT 
12. Kei 2010 Singapore 12 Retrospective case series Yes 
13. Keidar 2008 Israel 48 Prospective case series; 
Only immunocompetent 
Yes 
14. Kim 2012 South Korea 48 Retrospective case series; 
Only immunocompetent 
Yes 
15. Kubota 2011 Japan 81 Retrospective case series Yes 
16. Manohar 2013 India 103 Retrospective case series Yes 
17. Martin 2013 Belgium 20 Retrospective case series No- Only HIV patients 
and only reviewed 
abnormal scans.  
18. Pedersen 2012 Denmark 22 Retrospective case series; 
Only immunocompetent 
Yes 
19. Pelosi 2011 Italy 24 Retrospective case series; 
Only immunocompetent 
Yes 
20. Pereira 2016 Switzerland 76 Retrospective case series Yes 
21. Sheng 2011 China 48 Prospective case series; 
Only immunocompetent 
Yes 
22. Tokmak 2014 Turkey 25 Retrospective case series; 
Only immunocompetent 
Yes 
 
 
 
 
 
 
 
 
 
5) Subgroup analysis of the primary outcome, Diagnostic Yield 
Figure A: Subgroup Analysis for Diagnostic Yield of FDG-PET/CT only in adults with FUO, (n=15), 
Proportion 0=0% to 1=100% +/- 95% CI. The size of the grey box provides a measure of the sample 
size. I2>50% implies moderate heterogeneity.  
 
 
 
 
  
Figure B: Subgroup Analysis for Diagnostic Yield of FDG-PET/CT only in immunocompetent patients 
with FUO, (n=10), Proportion 0=0% to 1=100% +/- 95% CI. The size of the grey box provides a 
measure of the sample size. I2>50% implies moderate heterogeneity. 
 
 
  
 
  
Figure C: Subgroup Analysis for Diagnostic Yield of FDG-PET/CT only in immunocompetent adults 
patients with FUO, (n=9), Proportion 0=0% to 1=100% +/- 95% CI. The size of the grey box provides 
a measure of the sample size. I2>50% implies moderate heterogeneity. 
 
 
 
  
Figure D: Subgroup Analysis for Diagnostic Yield of FDG-PET/CT only in immunocompetent adults 
with FUO without contrast,  (n=8), Proportion 0=0% to 1=100% +/- 95% CI. The size of the grey box 
provides a measure of the sample size. I2>50% implies moderate heterogeneity. 
 
 
 
 
 
 
  
5) Forest plots for secondary outcomes: 
 
Figure E: Abnormal FDG-PET/CT in Fever of Unknown Origin (n=18), Proportion 0=0% to 1=100% 
+/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 
moderate heterogeneity. 
 
  
  
Figure F: False Positives of FDG-PET/CT in Fever of Unknown Origin (n=18), Proportion 0=0% to 
1=100% +/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 
moderate heterogeneity. 
 
 
  
Figure G: Final Diagnosis of Fever of Unknown Origin identified (n=18), Proportion 0=0% to 1=100% 
+/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 
moderate heterogeneity. 
 
 
 
  
Figure H: Infectious Final Diagnoses in Fever of Unknown Origin (n=18), Proportion 0=0% to 
1=100% +/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 
moderate heterogeneity. 
 
 
 
 
  
Figure I: Inflammatory Final Diagnoses in Fever of Unknown Origin (n=18), Proportion 0=0% to 
1=100% +/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 
moderate heterogeneity. 
 
 
 
 
  
Figure J: Malignancy as Final Diagnoses in Fever of Unknown Origin (n=18), Proportion 0=0% to 
1=100% +/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 
moderate heterogeneity. 
 
 
 
 
 
Highlights 
 A systematic review identified 18 eligible studies, 905 patients, of FDG-PET/CT in FUO 
 Pooled diagnostic yield was 56% (95%CI 50-61%), I2=61% 
 Sub-group analysis of diagnostic yield over conventional CT was 32% (95%CI 22-44%) I2=66% 
 Iterative Delphi Surveys generated interspeciality consensus on the topic.  
 There is insufficient evidence to support the value of FDG-PET/CT in investigative algorithms 
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